Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation.

Cell biochemistry and biophysics - 1 Jan 2008

Kundrapu Kanakadurga, Colenberg Latoya, Duhé Roy J

Abstract excerpt

A gain-of-function mutation (V617F) in the pseudokinase domain of JAK2 is frequently present in patients with myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. This mutation might serve as an important diagnostic biomarker for these uncommon diseases and may represent a target for novel therapy. It is imperative that a well-defined molecular mechanism be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Activation
Share to JAK2 gene
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Phosphorylation

Share to Recombinant Proteins

Share to Signal Transduction

Share to Tyrosine

Source

Identifiers

PMID: 18841497
DOI: 10.1007/s12013-008-9025-4

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation.PMID 18841497Read ↗

Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.Semantic proximity Read ↗

JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.Semantic proximity Read ↗

JAK2 activation in myeloproliferative neoplasms: a potential role for heterodimeric receptors.Semantic proximity Read ↗

A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F).Semantic proximity Read ↗

A novel germline hyperactivating JAK2 mutation L604F.Semantic proximity Read ↗

Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.Semantic proximity Read ↗

Gain of function in Jak2V617F-positive T-cells.Semantic proximity Read ↗

Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.Semantic proximity Read ↗

Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.Semantic proximity Read ↗

Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.Semantic proximity Read ↗

New insights into the structure and function of the pseudokinase domain in JAK2.Semantic proximity Read ↗

JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.